CN100361689C - 降脂颗粒组合物及其制备方法 - Google Patents
降脂颗粒组合物及其制备方法 Download PDFInfo
- Publication number
- CN100361689C CN100361689C CNB2005100597935A CN200510059793A CN100361689C CN 100361689 C CN100361689 C CN 100361689C CN B2005100597935 A CNB2005100597935 A CN B2005100597935A CN 200510059793 A CN200510059793 A CN 200510059793A CN 100361689 C CN100361689 C CN 100361689C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- preparation
- parts
- folium nelumbinis
- herb gynostemmae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004369 blood Anatomy 0.000 title abstract description 63
- 239000008280 blood Substances 0.000 title abstract description 63
- 239000000203 mixture Substances 0.000 title abstract description 10
- 238000000034 method Methods 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 62
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 239000009636 Huang Qi Substances 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 22
- 241000756943 Codonopsis Species 0.000 claims description 13
- 235000008216 herbs Nutrition 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 10
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 4
- 241000522254 Cassia Species 0.000 claims description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- -1 and filters Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 18
- 230000017531 blood circulation Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 108010011485 Aspartame Proteins 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000012109 statistical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 241000746998 Tragus Species 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- ZXKXJHAOUFHNAS-UHFFFAOYSA-N fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+]C(C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量g/mg | 给药前CHO(mmol/L) | 药后血脂 | |||
CHO(mmol/L) | TG(mmol/L) | LDL-C(mmol/L) | HDL-C(mmol/L) | |||
对照组模型组降脂灵降脂颗粒 | --2.57.23.61.8 | 2.88±0.612.83±0.872.97±0.382.91±0.672.86±0.712.93±0.54 | 2.53±0.667.01±2.54##4.38±1.34<sup>**</sup>4.30±1.14<sup>**</sup>4.53±1.16<sup>*</sup>4.93±1.79 | 0.72±0.301.55±0.66##0.95±0.31<sup>*</sup>0.82±0.30<sup>**</sup>0.96±0.47<sup>*</sup>1.02±0.72 | 1.41±0.846.55±3.41##3.41±1.65<sup>*</sup>2.92±1.44<sup>**</sup>3.27±1.28<sup>*</sup>3.50±2.31<sup>*</sup> | 1.13±0.320.53±0.12##0.74±0.23<sup>*</sup>0.79±0.28<sup>*</sup>0.72±0.26<sup>*</sup>0.70±0.23 |
组别 | 剂量g/mg | N | 全血粘度(切变率1/s) | |||
5 | 10 | 38 | 150 | |||
对照组模型组降脂灵降脂颗粒 | --2.57.23.61.8 | 101010101010 | 9.92±0.4312.5±1.35##11.1±1.5310.7±1.17<sup>**</sup>10.8±1.33<sup>*</sup>11.4±2.53 | 7.40±0.219.12±0.97##8.16±1.05<sup>*</sup>7.93±0.75<sup>**</sup>7.92±0.93<sup>*</sup>8.30±1.63 | 4.90±0.185.86±0.64##5.30±0.685.18±0.41<sup>*</sup>5.09±0.58<sup>*</sup>5.26±0.83 | 3.81±0.214.44±0.51##4.04±0.523.98±0.31<sup>*</sup>3.86±0.44<sup>*</sup>3.94±0.54<sup>*</sup> |
组别 | 剂量g/kg | 给药前CHO(mmol/L) | 药后血脂 | |||
CHO(mmol/L) | TG(mmol/L) | LDL-C(mmol/L) | HDL-C(mmol/L) | |||
对照组模型组降脂灵降脂颗粒 | --2.57.23.61.8 | 3.13±1.599.48±2.53##10.63±4.24##10.62±3.28##10.41±2.86##9.91±2.66## | 2.87±0.777.56±2.13##5.07±1.51<sup>**</sup>4.04±1.96<sup>**</sup>4.65±2.01<sup>**</sup>4.76 ±2.52<sup>*</sup> | 1.83±0.583.23±0.57##2.13±0.85<sup>**</sup>2.38±0.61<sup>**</sup>2.19±0.79<sup>**</sup>2.43±0.77 | 2.27±0.786.25±1.97##4.23±1.53<sup>*</sup>3.33±1.91<sup>**</sup>3.76±1.99<sup>*</sup>3.85 ±2.59<sup>*</sup> | 0.96±0.350.54±0.22##0.81±0.23<sup>*</sup>0.71±0.11<sup>*</sup>0.59±0.19<sup>*</sup>0.77±0.22<sup>*</sup> |
组别 | 剂量g/kg | N | 全血粘度(切变率 l/s) | |||
5 | 10 | 38 | 150 | |||
对照组模型组降脂灵降脂颗粒 | --2.57.23.61.8 | 101010101010 | 9.96±1.8513.2±1.69##11.4±1.81<sup>*</sup>10.1±2.16<sup>**</sup>11.2±1.67<sup>*</sup>10.9±1.56<sup>**</sup> | 7.42±1.329.42±1.0##8.39±1.05<sup>*</sup>7.44±1.55<sup>**</sup>8.07±1.12<sup>*</sup>7.93±0.97 | 4.91±0.825.83±0.62#5.37±0.704.87±0.88<sup>*</sup>5.07±0.66<sup>*</sup>5.07±0.51<sup>*</sup> | 3.71±0.454.31±0.60#4.04±0.633.72±0.653.78±0.513.83±0.40 |
组别 | 剂量(g/kg) | 鼠数(只) | 血流速度 | 恢复时间 | |
造模前 | 造模后 | (分) | |||
对照组 | - | 10 | 3.8±0.42 | 0.90±0.46 | 21.5±4.25 |
降脂颗粒 | 10.8 | 10 | 3.8±0.42 | 1.70±0.48<sup>**</sup> | 16.5±5.70<sup>*</sup> |
5.4 | 10 | 3.7±0.48 | 1.50±0.53<sup>*</sup> | 16.2±5.03<sup>*</sup> | |
2.7 | 10 | 3.8±0.42 | 1.45±0.60<sup>*</sup> | 16.9±7.37 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100597935A CN100361689C (zh) | 2005-04-01 | 2005-04-01 | 降脂颗粒组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100597935A CN100361689C (zh) | 2005-04-01 | 2005-04-01 | 降脂颗粒组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1839944A CN1839944A (zh) | 2006-10-04 |
CN100361689C true CN100361689C (zh) | 2008-01-16 |
Family
ID=37029247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100597935A Expired - Fee Related CN100361689C (zh) | 2005-04-01 | 2005-04-01 | 降脂颗粒组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100361689C (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102366496A (zh) * | 2007-08-07 | 2012-03-07 | 北京北大维信生物科技有限公司 | 中草药泽泻提取物在制备减肥降脂药物或制备具有脂肪酶活性抑制作用的药物中的应用 |
CN105311362A (zh) * | 2014-07-04 | 2016-02-10 | 蚌埠丰原涂山制药有限公司 | 一种治疗高血脂的中草药组合物及其制备方法 |
CN104146097A (zh) * | 2014-08-20 | 2014-11-19 | 西安和缘堂药业科技有限公司 | 一种降血脂茶及其制备方法 |
CN104208312A (zh) * | 2014-09-29 | 2014-12-17 | 崔银方 | 一种治疗高血脂症的药物 |
CN104706763B (zh) * | 2015-01-31 | 2017-12-26 | 江苏神华药业有限公司 | 一种具有预防或降低血脂作用的药物组合物及其制备方法 |
CN106421550A (zh) * | 2016-11-30 | 2017-02-22 | 上海市同仁医院 | 一种治疗脂肪肝的中药组合物及其制备方法 |
CN108186926A (zh) * | 2018-03-07 | 2018-06-22 | 田洪斋 | 一种活血通经的中药药物 |
CN109527273A (zh) * | 2019-01-15 | 2019-03-29 | 无锡华诺威动物保健品有限公司 | 一种保护特种水产鱼类肝脏健康的饲料添加剂及制备方法 |
CN110101792A (zh) * | 2019-06-19 | 2019-08-09 | 北京中医药大学 | 具有降脂作用的中药组合物及其制备方法和用途 |
CN111088141A (zh) * | 2019-12-24 | 2020-05-01 | 内蒙古中健宝生物科技有限公司 | 一种可调节代谢的保健酒的制备方法及由其制备的保健酒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1413728A (zh) * | 2002-10-09 | 2003-04-30 | 张铁良 | 一种治疗冠心病的中药组合物及其制备方法 |
-
2005
- 2005-04-01 CN CNB2005100597935A patent/CN100361689C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1413728A (zh) * | 2002-10-09 | 2003-04-30 | 张铁良 | 一种治疗冠心病的中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1839944A (zh) | 2006-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100361689C (zh) | 降脂颗粒组合物及其制备方法 | |
CN1326554C (zh) | 一种抗肿瘤药 | |
CN104491751B (zh) | 一种治疗脂肪肝合并高血脂症的中药组合物及其制备方法 | |
CN101816739B (zh) | 一种中药组合物及其制备方法 | |
CN102488743B (zh) | 中药组合物、制备方法及中药制剂 | |
CN102114099B (zh) | 抑制肝癌的中药制剂及其制备方法 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN1167452C (zh) | 治疗艾滋病的药 | |
CN101537159B (zh) | 一种中药组合物及其制备方法和应用 | |
CN102657736B (zh) | 一种治疗类风湿性关节炎的药物组合物及其制备方法 | |
CN101342249B (zh) | 一种治疗乙肝的中药制剂及其制备方法 | |
CN1969940A (zh) | 一种抗病毒药用组合物 | |
CN104771589A (zh) | 一种治疗脂肪肝的中药组合物及其应用 | |
CN102872385B (zh) | 一种治疗晚期胃癌的复方中药组合物及其制备方法和应用 | |
CN106511915A (zh) | 一种复方中药组合物在抑制皮肤黑色素瘤肺转移药物中的应用 | |
CN109876127A (zh) | 一种养血当归胶囊及其制备方法 | |
CN101199667A (zh) | 一种治疗白血病、再生障碍性贫血的中药制剂 | |
CN102366594A (zh) | 一种用于调节月经的中药 | |
CN101829213B (zh) | 治疗哮喘的药物组合物及其制备方法 | |
CN100411670C (zh) | 一种治疗上消化道肿瘤的药物及其制备方法 | |
CN1042495C (zh) | 一种益气消癌升高白细胞的药物及其制备方法 | |
CN105362966A (zh) | 一种制备治疗脂肪肝的中药制剂的方法 | |
CN1340353A (zh) | 一种治疗肝病的口服药及其制备方法 | |
CN115501314A (zh) | 一种抑制肿瘤肝转移的复方中药组合物及其制备方法与应用 | |
CN104547945A (zh) | 一种治疗淋巴结核的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Effective date: 20110824 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100070 FENGTAI, BEIJING TO: 748000 DINGXI, GANSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110824 Address after: 748000, Zhongtian County, Changan Road, Longxi County, Gansu Province Patentee after: LONGXI ZHONGTIAN PHARMACEUTICAL Co.,Ltd. Address before: 100070 Beijing Fengtai District Branch Road No. 9 room 406 Patentee before: Beijing Zhaohan Medical Technique Institute |
|
TR01 | Transfer of patent right |
Effective date of registration: 20201116 Address after: 748000 North Road, Changan Road, Longxi County, Gansu, Dingxi Patentee after: GANSU ZHONGTIAN JINDAN PHARMACEUTICAL Co.,Ltd. Address before: 748000, Zhongtian County, Changan Road, Longxi County, Gansu Province Patentee before: LONGXI ZHONGTIAN PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080116 |
|
CF01 | Termination of patent right due to non-payment of annual fee |